Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases
A preventive and therapeutic drug for a neurodegenerative disease containing, as an active ingredient, a cyclohexenone long-chain alcohol compound represented by formula (1) wherein each of R 1 , R 2 , and R 3 represents a hydrogen atom or a methyl group; and X represents a C10–C28 alkylene group or alkenylene group. Since the compound of the present invention exhibits excellent neurite-extension ability and an inhibition effect on disorders caused by mutation in an SOD gene, it is useful as the active ingredient of a preventive and therapeutic drug for neurodegenerative diseases, inter alia, amyotrophic lateral sclerosis, and as the active ingredient of an inhibitory drug for disorders caused by mutation in an SOD gene.
1. A method for treating amyotrophic lateral sclerosis, which comprises:
administering to a subject in need thereof a cyclohexenone long-chain alcohol compound, pharmaceutically acceptable salt, solvate or hydrate thereof, represented by the following formula (1):
wherein each of R 1 , R 2 , and R 3 is a methyl group; and X is a C15–C28 linear alkylene group or a C15–C28 linear alkenylene group.
2. The method of claim 1 , wherein X is a C15–C28 linear alkylene group.
3. The method of claim 1 , wherein X is a C15–C28 linear alkenylene group.
4. The method of claim 1 , wherein the administering is orally, by injection or by suppository.
5. The method of claim 1 , wherein the daily dose for a human adult is 0.01–1000 mg.
6. The method of claim 1 , wherein the daily dose for a human adult is 0.1–100 mg.
7. A method for treating amyotrophic lateral sclerosis caused by mutation in a superoxide dismutase gene, which comprises:
administering to a subject in need thereof a cyclohexenone long-chain alcohol compound, pharmaceutically acceptable salt, solvate or hydrate thereof, represented by the following formula (1):
wherein each of R 1 , R 2 , and R 3 is a methyl group; and X is a C15–C28 linear alkylene group or a C15–C28 linear alkenylene group.
8. The method of claim 7 , wherein the administering is orally, by injection or by suppository.
9. The method of claim 7 , wherein the daily dose for a human adult is 0.01–1000 mg.
10. The method of claim 7 , wherein the daily dose for a human adult is 0.1–100 mg.